You are here

  • Home
  • Archive
  • Volume 73, Issue Suppl 2
  • FRI0264 A Randomized, Single-Blind, Single-Dose, Three-Arm, Parallel Group Study in Healthy Subjects to Demonstrate Pharmacokinetic Equivalence of ABP 501 and Adalimumab: Results of Comparison with Adalimumab (EU)

Citation Tools

Article menu
Download PDFPDF
EULAR 2014: Scientific Abstracts
Poster Presentations. Rheumatoid arthritis - anti-TNF therapy
FRI0264 A Randomized, Single-Blind, Single-Dose, Three-Arm, Parallel Group Study in Healthy Subjects to Demonstrate Pharmacokinetic Equivalence of ABP 501 and Adalimumab: Results of Comparison with Adalimumab (EU)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Kaur P, Chow V, Zhang N, et al
FRI0264 A Randomized, Single-Blind, Single-Dose, Three-Arm, Parallel Group Study in Healthy Subjects to Demonstrate Pharmacokinetic Equivalence of ABP 501 and Adalimumab: Results of Comparison with Adalimumab (EU)
Annals of the Rheumatic Diseases 2014;73:479.